Skip to main content
. 2018 Jan 17;2018(1):CD000209. doi: 10.1002/14651858.CD000209.pub3

Adler 1993.

Methods Allocation: "random allocation", ratio of 3 vitamin E: 2 placebo.
 Double‐blind: no further details.
 Duration: 36 weeks (preceded by 2 week washout).
 Setting: inpatients and outpatients of the Department of Veterans Affairs Medical Center, USA.
 Design: parallel group.
Participants Diagnosis: schizophrenia, depression (no criteria) and antipsychotic‐induced TD (Research Diagnostic Criteria, Schooler and Kane).
 N = 40*.
 Sex: 2 female, 27 male*.
 Age: average vitamin E 58.0 (SD 9.5) years; placebo 61.0 (SD 9.2) years*
Interventions 1. Vitamin E: dose increasing over 3 weeks to 1600 IU/day. N = 24.**
 2. Placebo. N = 16.**
 Stable antipsychotic medication: dose average (CPE) vitamin E = 536 mg/day (SD 642); placebo = 921 mg/day (SD 1026). Compliance assessed by pill counts.
Outcomes TD symptoms: AIMS.
 Leaving the study early.
Notes * initial report at 8 weeks, N = 29.
 ** three people left the study in the first 2 weeks and could not be considered in the analysis ‐ original group assumed from 3:2 randomisation.
Source of funding: Supported in part by the Department of Veterans Affairs.
Declarations of interest: Not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk "Patients were randomly assigned to treatment with Vitamin E, 400IU, or one matching placebo capsule, by mouth, b.i.d." No further details
Allocation concealment (selection bias) Unclear risk "We used a randomization of 3:2 (vitamin E to placebo) to maximize the number of patients receiving active treatment while maintaining the blind". No further details
Blinding of participants and personnel (performance bias) Unclear risk "Both rater and patient were blind to the patient's drug assignment". No further details
Blinding of outcome assessment (detection bias) Unclear risk "Both rater and patient were blind to the patient's drug assignment". No further details
Incomplete outcome data (attrition bias) 
 All outcomes Low risk “One patient dropped out after 2 weeks due to non‐compliance” “Two patients developed significant medical illnesses ... unrelated to study treatment”, “By prior design, treatment for the first 8 patients was terminated after 8 weeks.”
Selective reporting (reporting bias) Unclear risk All expected outcomes have been reported but there is no study protocol to confirm that all planned outcomes were reported.
Other bias Unclear risk Baseline AIMS scores were somewhat higher in the vitamin E group than in the placebo group, however, this difference was not statistically significant. Small sample size